title: Risk stratification for cancer-associated venous thromboembolism.
abstract: The risk of venous thromboembolism (VTE) is elevated in cancer, and thrombosis is the second leading cause of death in patients with malignancy. Many risk factors for cancer-associated thrombosis have been identified. These include patient-associated factors such as age, obesity and medical comorbidities; cancer-associated factors such as site and stage of cancer; and treatment-associated factors, particularly chemotherapy and hospitalization. In addition, several candidate biomarkers for cancer-associated thrombosis have been identified recently. Despite the high rate and significant impact of VTE in cancer outpatients, prior attempts at thromboprophylaxis in this population have not consistently demonstrated a benefit. This chapter will focus on risk stratification approaches, including a recently developed predictive model which can be used to identify those patients at highest risk. This model-based approach may have a significant impact on cancer-related morbidity, mortality and cost of care by directing targeted thromboprophylaxis in the future.
authors.affiliation: James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA.
authors.forename: Gregory C
authors.initials: GC
authors.lastname: Connolly
authors.forename: Alok A
authors.initials: AA
authors.lastname: Khorana
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000150:complications* / Q000401:mortality / Q000473:pathology / Q000628:therapy
chemical_list: D020533:Angiogenesis Inhibitors